

Novel approaches in the therapy of metastatic renal cell

World Journal of Urology

23, 202-212

DOI: 10.1007/s00345-004-0466-0

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1295-1304.	1.1	4
2	Sunitinib malate for the treatment of solid tumours: a review of current clinical data. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 553-561.	1.9	108
3	Parathyroid hormone-related protein in human renal cell carcinoma. <i>Cancer Letters</i> , 2006, 240, 170-182.	3.2	41
5	Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. <i>Proteomics</i> , 2006, 6, 2853-2864.	1.3	75
6	Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 137-149.	1.2	36
7	Treatment options in renal cell carcinoma: past, present and future. <i>Annals of Oncology</i> , 2007, 18, x25-x31.	0.6	59
8	Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Outcome. <i>Clinical Cancer Research</i> , 2007, 13, 697s-702s.	3.2	68
9	Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials: Fig. 1.. <i>Clinical Cancer Research</i> , 2007, 13, 703s-708s.	3.2	31
10	Characterization of Primary Renal Carcinoma Cultures. <i>Urologia Internationalis</i> , 2007, 79, 235-243.	0.6	10
12	Current options for the treatment of locally advanced and metastatic renal cell carcinoma: focus on sunitinib. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 4-11.	2.2	2
13	Key considerations in patient selection for the use of targeted therapy in metastatic renal cell carcinoma. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 20-27.	2.2	4
14	Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 115-124.	13.9	5,409
16	Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. <i>BMC Cancer</i> , 2007, 7, 133.	1.1	58
17	Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. <i>World Journal of Urology</i> , 2007, 25, 59-72.	1.2	9
18	Angiogenesis and angiogenic inhibitors in renal cell carcinoma. <i>Current Urology Reports</i> , 2008, 9, 26-33.	1.0	13
19	CrÃ©ation d'une unit� de coordination de la prise en charge des tumeurs rares du rein de l'adulte. <i>Oncologie</i> , 2008, 10, 437-442.	0.2	0
20	Serum biomarker discovery in renal cancer using 2DE and prefractionation by immunodepletion and isoelectric focusing; increasing coverage or more of the same?. <i>Proteomics</i> , 2008, 8, 5074-5085.	1.3	33
21	The burden of renal cell cancer: A retrospective longitudinal study on occurrence, outcomes and cost using an administrative claims database. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 46-51.	2.2	5

#	ARTICLE	IF	CITATIONS
22	Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. <i>Cancer Treatment Reviews</i> , 2008, 34, 193-205.	3.4	832
23	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 232-244.	1.0	9
24	Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFN γ in Patients with Good Prognosis Metastatic Renal Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 5907-5912.	3.2	26
25	Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2009, 2, 51.	1.0	30
26	Pharmacokinetics of sunitinib in hemodialysis. <i>Annals of Oncology</i> , 2009, 20, 190-192.	0.6	52
27	Prognostic markers and targeted therapies for renal cell carcinoma. <i>Future Oncology</i> , 2009, 5, 197-205.	1.1	0
28	Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4068-4075.	0.8	188
29	Phase I Trial of Sunitinib Malate plus Interferon- γ for Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 28-33.	0.9	62
30	Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. <i>International Journal of Cancer</i> , 2009, 125, 474-482.	2.3	93
31	Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer. <i>Drug Safety</i> , 2009, 32, 717-734.	1.4	32
32	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology</i> , The, 2009, 10, 757-763.	5.1	571
33	Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients. <i>World Journal of Urology</i> , 2010, 28, 311-317.	1.2	2
34	A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 429-38.	0.7	13
35	NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation. <i>British Journal of Cancer</i> , 2010, 102, 873-882.	2.9	31
36	Management of metastatic renal cell carcinoma in patients with poor prognosis. <i>Cancer Management and Research</i> , 2010, , 123.	0.9	5
37	Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience. <i>Korean Journal of Urology</i> , 2010, 51, 450.	1.2	14
38	Combination Therapy of Interleukin-2 and Sorafenib Improves Survival Benefits and Prevents Spontaneous Pulmonary Metastasis in Murine Renal Cell Carcinoma Models. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 503-507.	0.6	6
39	A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 194-202.	0.6	133

#	ARTICLE	IF	CITATIONS
40	Treatment of Hemodialyzed Patients with Sunitinib in Renal Cell Carcinoma. <i>Chemotherapy</i> , 2010, 56, 485-491.	0.8	18
41	Laparoscopic Cytoreductive Nephrectomy: A Three-Center Retrospective Analysis. <i>Journal of Endourology</i> , 2010, 24, 1451-1455.	1.1	8
42	Severe Dyspnea due to Pulmonary Metastasis of Renal Cell Carcinoma: Is Cytoreductive Surgery of Value. <i>Case Reports in Oncology</i> , 2010, 3, 339-343.	0.3	2
43	Progress in the Management of Advanced Renal Cell Carcinoma (RCC). <i>Aktuelle Urologie</i> , 2010, 41, S57-S60.	0.3	0
44	Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1005-1015.	1.5	11
45	Linkage of microRNA and Proteome-Based Profiling Data Sets: A Perspective for the Priorization of Candidate Biomarkers in Renal Cell Carcinoma?. <i>Journal of Proteome Research</i> , 2011, 10, 191-199.	1.8	11
46	Axitinib for the Management of Metastatic Renal Cell Carcinoma. <i>Drugs in R and D</i> , 2011, 11, 113-126.	1.1	130
47	Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. <i>European Journal of Cancer</i> , 2011, 47, 1955-1961.	1.3	111
48	Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 2592-2602.	1.3	108
49	Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2011, 37, 180-186.	0.7	5
50	Vaccines for Colorectal Cancer and Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 283-293.	1.0	6
51	Combination therapy for renal cell carcinoma: review of the clinical evidence. <i>Clinical Investigation</i> , 2011, 1, 689-697.	0.0	0
52	Spontaneous Regression of Multiple Pulmonary Metastases After Radiofrequency Ablation of a Single Metastasis. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 424-430.	0.9	47
54	Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. <i>Annals of Oncology</i> , 2011, 22, 794-800.	0.6	116
55	An overview of angiogenesis and renal cell carcinoma. <i>International Journal of Nutrition, Pharmacology, Neurological Diseases</i> , 2012, 2, 3.	0.6	7
56	Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication. <i>Case Reports in Oncological Medicine</i> , 2012, 2012, 1-5.	0.2	4
57	Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. <i>British Journal of Cancer</i> , 2012, 107, 1665-1671.	2.9	97
58	CD146 gene expression in clear cell renal cell carcinoma: a potential marker for prediction of early recurrence after nephrectomy. <i>International Urology and Nephrology</i> , 2012, 44, 1663-1669.	0.6	19

#	ARTICLE	IF	CITATIONS
59	Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2012, 39, 211-231.	0.8	24
60	The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 202-208.	1.3	170
61	Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 1031-1037.	1.3	49
62	DDX31 Regulates the p53-HDM2 Pathway and rRNA Gene Transcription through Its Interaction with NPM1 in Renal Cell Carcinomas. <i>Cancer Research</i> , 2012, 72, 5867-5877.	0.4	35
63	Targeting the Tumor Microenvironment: Focus on Angiogenesis. <i>Journal of Oncology</i> , 2012, 2012, 1-16.	0.6	93
64	Epigenetic regulation in RCC: opportunities for therapeutic intervention?. <i>Nature Reviews Urology</i> , 2012, 9, 147-155.	1.9	51
65	Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. <i>Medical Oncology</i> , 2012, 29, 750-754.	1.2	10
66	Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2012, 19, 796-804.	0.5	8
67	Chromophobe renal cell carcinoma: A review of an uncommon entity. <i>International Journal of Urology</i> , 2012, 19, 894-900.	0.5	85
68	Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. <i>BMC Clinical Pathology</i> , 2013, 13, 3.	1.8	15
69	Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease. <i>Journal of Translational Medicine</i> , 2013, 11, 255.	1.8	32
70	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. <i>European Journal of Cancer</i> , 2013, 49, 2134-2142.	1.3	60
71	VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. <i>British Journal of Cancer</i> , 2013, 108, 1126-1132.	2.9	71
72	Optimal management of renal cell carcinoma in the elderly: a review. <i>Clinical Interventions in Aging</i> , 2013, 8, 433.	1.3	35
73	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.. <i>Canadian Urological Association Journal</i> , 2014, 8, 121.	0.3	8
74	Erfolge und Grenzen zielgerichteter Therapien beim Nierenzellkarzinom. <i>Karger Kompass Onkologie</i> , 2014, 1, 66-74.	0.0	0
75	GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma. <i>British Journal of Cancer</i> , 2014, 110, 2250-2260.	2.9	34
76	Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma. <i>Progress in Tumor Research</i> , 2014, 41, 98-112.	0.1	8

#	ARTICLE	IF	CITATIONS
77	Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies. <i>PLoS ONE</i> , 2014, 9, e114264.	1.1	35
78	Downregulation of the tumor suppressor HSPB7, involved in the p53 pathway, in renal cell carcinoma by hypermethylation. <i>International Journal of Oncology</i> , 2014, 44, 1490-1498.	1.4	25
79	Prognostic impact of baseline serum α -reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. <i>BJU International</i> , 2014, 114, 81-89.	1.3	68
80	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. <i>Future Oncology</i> , 2014, 10, 1361-1372.	1.1	9
81	Renal cell carcinoma metastasis to the parathyroid gland: A very rare occurrence. <i>International Journal of Surgery Case Reports</i> , 2014, 5, 378-380.	0.2	5
82	Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?. <i>World Journal of Urology</i> , 2014, 32, 39-45.	1.2	9
83	Diffusion-weighted imaging of focal renal lesions: a meta-analysis. <i>European Radiology</i> , 2014, 24, 241-249.	2.3	116
84	Can Initial 18F-FDG PET-CT Imaging Give Information on Metastasis in Patients with Primary Renal Cell Carcinoma?. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 144-152.	0.6	17
85	Sarcomatoid Dedifferentiation in Metastatic Clear Cell Renal Cell Carcinoma and Outcome on Treatment With Anti-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Retrospective Analysis. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e205-e214.	0.9	33
86	Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Oncologist</i> , 2014, 19, 51-60.	1.9	57
87	Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. <i>World Journal of Urology</i> , 2014, 32, 615-622.	1.2	18
88	High-dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: A Contemporary Experience. <i>Urology</i> , 2014, 83, 1129-1134.	0.5	24
89	Expression profiling of metastatic renal cell carcinoma using gene set enrichment analysis. <i>International Journal of Urology</i> , 2014, 21, 46-51.	0.5	15
90	Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study. <i>Forum of Clinical Oncology</i> , 2015, 6, 23-27.	0.1	1
91	Cytoplasmic Accumulation of Heterogeneous Nuclear Ribonucleoprotein K Strongly Promotes Tumor Invasion in Renal Cell Carcinoma Cells. <i>PLoS ONE</i> , 2015, 10, e0145769.	1.1	20
92	Potentials of Interferon Therapy in the Treatment of Pancreatic Cancer. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 327-339.	0.5	21
93	Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 280-286.	0.9	21
94	Axitinib in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 499-507.	1.1	13

#	ARTICLE	IF	CITATIONS
95	Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib. <i>European Radiology</i> , 2015, 25, 375-379.	2.3	13
96	Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1925-1934.	3.2	67
97	Axitinib: A Review in Advanced Renal Cell Carcinoma. <i>Drugs</i> , 2015, 75, 1903-1913.	4.9	40
98	Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma. <i>Oncology Letters</i> , 2016, 12, 1265-1270.	0.8	12
99	An integrative and comparative study of pan-cancer transcriptomes reveals distinct cancer common and specific signatures. <i>Scientific Reports</i> , 2016, 6, 33398.	1.6	31
100	Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e575-e583.	0.9	10
101	Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma. <i>International Urology and Nephrology</i> , 2016, 48, 1253-1260.	0.6	12
102	Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. <i>Journal of Neurosurgery: Spine</i> , 2016, 25, 766-774.	0.9	51
103	Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer. <i>Nature Communications</i> , 2016, 7, 10656.	5.8	81
104	The effect of information on preferences for treatments of metastatic renal cell carcinoma. <i>Current Medical Research and Opinion</i> , 2016, 32, 1827-1838.	0.9	8
105	Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. <i>Current Medical Research and Opinion</i> , 2016, 32, 741-747.	0.9	12
106	A Systematic Review of the Prognostic Role of Hematologic Scoring Systems in Patients With Renal Cell Carcinoma Undergoing Nephrectomy With Curative Intent. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 271-276.	0.9	15
107	Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER Medicare Database Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e573-e582.	0.9	53
108	Can partial nephrectomy provide equal oncological efficiency and safety compared with radical nephrectomy in patients with renal cell carcinoma (≥4 cm)? A propensity score-matched study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 379-385.	0.8	36
109	Metastatic Renal Cell Carcinoma to Jejunum: An Unusual Case Presentation. <i>Urology Case Reports</i> , 2017, 13, 34-36.	0.1	4
110	Diagnostic and prognostic value of scavenger receptor class B type 1 in clear cell renal cell carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831769911.	0.8	11
111	Circulating Cell-Free DNA Levels in Patients with Metastatic Renal Cell Carcinoma. <i>Oncology Research and Treatment</i> , 2017, 40, 707-710.	0.8	7
112	Engrailed-2 promoter hypermethylation is associated with its downregulation in clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2017, 14, 6888-6894.	0.8	4

#	ARTICLE	IF	CITATIONS
113	Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 7, 454-460.	0.4	0
114	ABCG2 is a potential prognostic marker of overall survival in patients with clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2017, 17, 222.	1.1	6
115	Testicular Metastasis from Renal Cell Carcinoma: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2017, 10, 388-391.	0.3	8
116	Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems. <i>Translational Research</i> , 2017, 180, 1-11.	2.2	29
117	Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study. <i>Urology</i> , 2017, 99, 155-161.	0.5	17
118	Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. <i>Frontiers in Oncology</i> , 2017, 7, 107.	1.3	44
119	Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 799-806.	0.9	21
120	Non-coding RNA 886 promotes renal cell carcinoma growth and metastasis through the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway. <i>Molecular Medicine Reports</i> , 2017, 16, 4273-4278.	1.1	14
121	HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4635-4643.	1.0	10
122	GV1001 Induces Apoptosis by Reducing Angiogenesis in Renal Cell Carcinoma Cells Both In Vitro and In Vivo. <i>Urology</i> , 2018, 113, 129-137.	0.5	8
123	Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 88.	1.1	36
124	Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 79.e19-79.e26.	0.8	5
125	Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting. <i>Current Oncology</i> , 2018, 25, 576-584.	0.9	16
126	Renal cell carcinoma presenting as nonspecific gastrointestinal symptoms: a case report. <i>International Medical Case Reports Journal</i> , 2018, Volume 11, 345-348.	0.3	2
127	Cytopathological Study of the Circulating Tumor Cells filtered from the Cancer Patients's Blood using Hydrogel-based Cell Block Formation. <i>Scientific Reports</i> , 2018, 8, 15218.	1.6	15
128	Down-regulation of ETS2 inhibits the invasion and metastasis of renal cell carcinoma cells by inducing EMT via the PI3K/Akt signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2018, 104, 119-126.	2.5	11
129	PTBP1 knockdown in renal cell carcinoma inhibits cell migration, invasion and angiogenesis in vitro and metastasis in vivo via the hypoxia inducible factor-1 pathway. <i>International Journal of Oncology</i> , 2018, 52, 1613-1622.	1.4	19
130	The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 335-343.	0.5	14

#	ARTICLE	IF	CITATIONS
131	Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 525-533.	0.5	9
132	SFRP1 Promoter Methylation and Renal Carcinoma Risk: A Systematic Review and Meta-Analysis. <i>Journal of Nippon Medical School</i> , 2018, 85, 78-86.	0.3	10
133	Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China. <i>Journal of Medical Economics</i> , 2018, 21, 1150-1158.	1.0	19
134	Toxicity mechanism-based prodrugs: glutathione-dependent bioactivation as a strategy for anticancer prodrug design. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 815-824.	2.5	12
135	Long noncoding RNA HOTAIR promotes renal cell carcinoma malignancy through alpha2,8-sialyltransferase 4 by sponging microRNA-124. <i>Cell Proliferation</i> , 2018, 51, e12507.	2.4	45
136	Comparisons of oncological outcomes and perioperative complications between laparoscopic and open radical nephrectomies in patients with clinical T2 renal cell carcinoma (≤7cm). <i>PLoS ONE</i> , 2018, 13, e0191786.	1.1	4
137	Renal Cell Carcinoma Metastasizing to Left Atrium With Coronary Sinus Invasion: A Rare Site of Metastasis Mimicking Myxoma. <i>Frontiers in Oncology</i> , 2019, 9, 738.	1.3	9
138	Radiation Therapy for Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2019, 3, 1-6.	0.2	2
139	Silencing of the long noncoding RNA GHET1 inhibits cell proliferation and migration of renal cell carcinoma through epithelial-mesenchymal transition. <i>Oncology Letters</i> , 2019, 17, 3173-3180.	0.8	4
140	Non-Cancer Drug Repurposing Candidates for Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 147-148.	1.0	1
141	Targeting the Deterministic Evolutionary Trajectories of Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 3300.	1.7	6
142	European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000798.	2.0	6
143	Intradural extramedullary spinal metastasis of renal cell carcinoma: illustrative case report and comprehensive review of the literature. <i>European Spine Journal</i> , 2020, 29, 176-182.	1.0	7
144	Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma. <i>Cancers</i> , 2020, 12, 3153.	1.7	15
145	Cell Polarity Protein Pals1-Associated Tight Junction Expression Is a Favorable Prognostic Marker in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 931.	1.1	6
146	Mandibular swelling as the initial presentation for renal cell carcinoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2020, 70, 96-100.	0.2	4
147	Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma. <i>Annals of Diagnostic Pathology</i> , 2020, 46, 151483.	0.6	16
148	Choice of Surgical Options in Kidney Cancer and Surgical Complications. <i>Seminars in Nephrology</i> , 2020, 40, 42-48.	0.6	10

#	ARTICLE	IF	CITATIONS
149	ETV4 is a theranostic target in clear cell renal cell carcinoma that promotes metastasis by activating the pro-metastatic gene FOSL1 in a PI3K-AKT dependent manner. <i>Cancer Letters</i> , 2020, 482, 74-89.	3.2	19
150	Dysregulation of the Sirt5/IDH2 axis contributes to sunitinib resistance in human renal cancer cells. <i>FEBS Open Bio</i> , 2021, 11, 921-931.	1.0	7
151	SLC39A8/Zinc Suppresses the Progression of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 651921.	1.3	5
152	Identification of a Risk Stratification Model to Predict Overall Survival and Surgical Benefit in Clear Cell Renal Cell Carcinoma With Distant Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 630842.	1.3	8
153	Genomic and Transcriptome Analysis to Identify the Role of the mTOR Pathway in Kidney Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-28.	1.9	5
154	Significance of preoperative hematologic scoring in predicting death among patients with non-metastatic renal cell carcinoma undergoing nephrectomy. <i>Asian Journal of Surgery</i> , 2021, 44, 952-956.	0.2	4
156	Population-based evaluation of the risk factors and prognosis among renal cell carcinoma patients with initially diagnosed lung metastases. <i>Actas Urológicas Españolas (English Edition)</i> , 2021, 45, 498-506.	0.2	1
157	Axitinib for the Management of Metastatic Renal Cell Carcinoma. <i>Drugs in R and D</i> , 2011, 11, 113-126.	1.1	2
158	Hypoxia and renal cell carcinoma: The influence of HIF1A + 1772C/T functional genetic polymorphism on prognosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 532.e25-532.e30.	0.8	2
159	Differential Expression of Prognostic Proteomic Markers in Primary Tumour, Venous Tumour Thrombus and Metastatic Renal Cell Cancer Tissue and Correlation with Patient Outcome. <i>PLoS ONE</i> , 2013, 8, e60483.	1.1	30
160	Simvastatin Inhibits Renal Cancer Cell Growth and Metastasis via AKT/mTOR, ERK and JAK2/STAT3 Pathway. <i>PLoS ONE</i> , 2013, 8, e62823.	1.1	121
161	Incidence and mortality of kidney cancers, and human development index in Asia; a matter of concern. <i>Journal of Nephropathology</i> , 2017, 6, 30-42.	0.1	37
162	Chrysophanic Acid Induces Necrosis but not Necroptosis in Human Renal Cell Carcinoma Caki-2 Cells. <i>Journal of Cancer Prevention</i> , 2016, 21, 81-87.	0.8	12
163	Methylation-Based Biomarkers for Early Detection of Urological Cancer. <i>Critical Reviews in Oncogenesis</i> , 2007, 13, 265-282.	0.2	10
164	Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 1204-1212.	0.8	6
165	Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 68854-68862.	0.8	5
166	Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression. <i>Oncotarget</i> , 2017, 8, 75076-75086.	0.8	10
167	Strengthening the foundation of kidney cancer treatment and research: revising the AJCC staging system. <i>Annals of Translational Medicine</i> , 2019, 7, S33-S33.	0.7	10

#	ARTICLE	IF	CITATIONS
168	Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 341-348.	0.9	187
170	First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience. <i>Indian Journal of Cancer</i> , 2017, 54, 626.	0.2	5
171	Aberrant Methylation of RASSF1A gene Contribute to the Risk of Renal Cell Carcinoma: a Meta-Analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 4665-4669.	0.5	7
173	Quality of Life in Advanced Renal Cell Carcinoma: Effect of Treatment with Cytokine Therapy and Targeted Agents. , 2010, , 2905-2922.		0
174	Erkrankungen der Nieren und Harnwege. , 2011, , 529-606.		0
175	Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. , 2013, , 155-177.		0
176	Clinical Significance of Soluble Major Histocompatibility Complex Class I Chain-related A in Renal Cell Carcinoma Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 5651-5655.	0.5	2
177	Quantitative Proteomics Analysis of Differentially Expressed Proteins Involved in Renal Clear Cell Carcinoma by Shotgun Approach Coupled with Stable Isotope Dimethyl Labeling. <i>Journal of Proteomics and Bioinformatics</i> , 2014, s7, .	0.4	1
178	Managing metastatic renal cell carcinoma-challenges, pitfalls, and outcomes in the real world. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2016, 37, 260-264.	0.1	1
179	Bilateral renal cell carcinoma with leiomyomatous stroma: A rare entity diagnosed synchronously and treated surgically in a staged fashion. <i>Turkish Journal of Urology</i> , 2017, 43, 566-570.	1.3	1
180	Microsatellite alteration and metylation of RASSF1 gene in renal cell carcinoma. <i>Faktori Eksperimental Noi Evolucii Organizmiv</i> , 0, 23, 192-196.	0.0	0
181	The Impact of Combination Therapy of Sunitinib with Interferon-Alpha on Survival of Patients with Loco Regional and Metastatic Clear Renal Cell Carcinoma. <i>International Journal of Cancer Management</i> , 2018, In Press, .	0.2	0
182	Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. , 2020, , 411-435.		0
184	Cell-Based Vaccines for Renal Cell Carcinoma. , 2008, , 475-488.		0
185	Management of metastatic renal cell carcinoma in patients with poor prognosis. <i>Cancer Management and Research</i> , 2010, 2, 123-32.	0.9	11
186	Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. <i>Canadian Journal of Urology</i> , 2011, 18, 5819-25.	0.0	17
187	Polypyrimidine Tract-Binding Protein 1 promotes proliferation, migration and invasion in clear-cell renal cell carcinoma by regulating alternative splicing of PKM. <i>American Journal of Cancer Research</i> , 2017, 7, 245-259.	1.4	20
188	Urinary metabolites for urological cancer detection: a review on the application of volatile organic compounds for cancers. <i>American Journal of Clinical and Experimental Urology</i> , 2019, 7, 232-248.	0.4	9

#	ARTICLE	IF	CITATIONS
189	Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists. <i>Frontiers in Oncology</i> , 2021, 11, 773366.	1.3	5
190	In Silico, In Vitro, and Clinical Investigations of Cathepsin B and Stefin A mRNA Expression and a Correlation Analysis in Kidney Cancer. <i>Cells</i> , 2022, 11, 1455.	1.8	8
191	Renal cell carcinoma with atypical metastases sites revealed by diabetes mellitus: A case report. <i>Annals of Medicine and Surgery</i> , 2022, 81, .	0.5	1
192	Integrating Surgery in the Multidisciplinary Care of Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2023, 50, 311-323.	0.8	2
193	The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer. <i>Urologic Clinics of North America</i> , 2023, 50, 285-303.	0.8	5
194	Parietal Nodular Lesion on The Scalp: Probable Renal Cell Carcinoma Metastasis - A Case Report. <i>Jornal Memorial Da Medicina</i> , 2022, 4, 23-28.	0.2	0
199	Current status and future perspective of immunotherapy for renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	0